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A novel reverse phase, isocratic HPLC method is described to separate five anti-diabetic drugs i.e., 
glimepiride, metformin, sitagliptin, rosiglitazone and pioglitazone. Nucleosil C18 analytical column 
was used as stationary phase, while mobile phase consisted of acetonitrile:phosphate buffer: methanol 
(40/40/20, v/v) pH 2.0. Effluent was monitored at a flow rate 1 mL/min and detected at wavelength of  
240 nm. This research produced excellent chromatography over a wide concentration range of 
25-10000 ng/mL. Sepprated and well resolved quantifiable peaks were obtained and test results were 
linear in this range. Correlation coefficient of more than 0.9990 was witnessed as well as Low %RSD 
values i.e., maximum 2.0% documented excellent precision of the method. Good recoveries from 
pharmaecutical (99-101%), urine and plasma samples (>96%) in a range of concentrtion granted very 
good linearity, accuracy and precision. The projected method has satisfactory applications in quality 
control of these molecules as well as quantification of these molecules in urine and plasma samples.
Keywords: Metformin/pharmacokinetics. High Pressure Liquid Chromatography, Urine/Plasma methods. 
Determination/prevention. Diabetes Mellitus/drug therapy. Drug Liberation/drug effects.
INTRODUCTION
Diabetes is a complicated disorder of endocrine 
system, wherein body do not produce insulin also known 
as (diabetes type1) or become resistance to the effect of 
insulin also known as (diabetes type II). As a result body 
blood sugar level remains consistently above normal. 
If it remains untreated, major complication may arise 
which affect various organs including eyes, kidneys, brain 
and heart (Kim, Newton, Knopp, 2002). A great deal of 
scientific activities is focused on the treatment of diabetes 
these days. Research in this area has produced new classes 
of medicines which are effective in countdown diabetic 
with less associated risks and harmful repercussions. 
These includes the biguanides such as metformin (MF), 
sulfonylureas such as glimepiride (GP), thiazolidinediones 
also known as PPARγ agonist such as pioglitazone (PGH), 
and rosiglitazone (RGM), meglitinides (repaglinide) 
and dipeptidyl peptidase IV (DPP-IV) inhibitor such as 
sitagliptin (SGP) etc. Although, type 1 and pre-diabetics 
can be controlled through monotherapy, however, its 
failure is non deniable fact in case of type II diabetes. To 
curb this menace generally combination therapy has been 
in practice (Valsamakis, Kumar, 2000). Co-administration 
of MF, GP, SGP, insulin and PPARγ agonist in whole 
or in part have resulted clinically meaningful glycemic 
improvements and is an ideal combination, considering 
contraindications, risk of hypoglycaemia, obesity and 
short and long term effectiveness (Fonseca et al., 2000; 
Goodarzi, Bryer‐Ash, 2005). Structures of MF,GP, SGP, 
PGH and RGM are shown in Figure 1.
MF is chemically defined as N,N-dimethyl-
imidodicarbonimidic diamide hydrochloride. It is an 
important hypoglycemic agent, designed as a first line 
therapy for type II diabetese. GP is chemically defined 
as 1-{(p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-
1-carboxamide)ethyl]phenyl)sulfonyl}-3-(trans-4-
methylcyclohexyl)urea. It stimulates pancreatic b-cells 
to secret insulin and is a useful combination for type II 
diabetic mellitus. SGP is named chemically as 7-[(3R)-
3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-
tetrahydo-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a] 
pyrazine phosphate. It is active, well-tolerated, and 
selective inhibitor of DPP-4, which enhances GLP-1 
concentration and provides glycemic improvement. PGH 
N. Sher, N. Fatima, S. Perveen, F. A. Siddiqui
Braz. J. Pharm. Sci. 2019;55:e17394Page 2 / 8
is a thiazolidinediones derivative, chemically defined as 
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl) thiazolidine-
2,4-dione), widely recommended in type II diabetes. 
RGM is another thiazolidinedione, chemically defined 
as (±)-5-[[4-{2-methyl-2-(pyridinylamino) ethoxy}
phenyl]methyl]methyl]-2,4-thiazolidinedione (Z)-2-
butenedioate (1:1)]. Both are established PPARs-γ agonist 
and exert their glucose lowering effect by making the cells 
more responsive to insulin (Katzung, Masters, Trevor, 
2004).
Drug industries and clinical laboratories are 
significantly interested in developing simultaneous 
analytical method. Anti-diabetic drugs are generally 
working together in form of bi or tri-therapy to combat 
the disease. Therefore, it is important to develop a 
validated analytical method which can quantitate these 
drugs individually as well as simultaneously. Literature 
survey revealed a number of reports for analysis of 
these molecules in pharmaceutical as well as biological 
samples. A protocol (Kolte et al., 2004) was developed for 
analysis of MF and PGH in pharmaceutical dosage form. 
Another report describes simultaneous quantification of 
MF, PGH and GP, in pharmaceutical samples (Jain et al., 
2008). Liquid chromatographic method for plasma level 
determination of anti-diabetic drugs (Aburuz, Millership, 
McElnay, 2005; Venkatesh et al., 2006) as well as anti-
diabetics in presence of some ACE inhibitors (Siddiqui 
et al, 2017) are well reported. GP and related impurities 
have been analyzed through liquid chromatography 
(Khan et al., 2005). Arayne et al. (2010, 2013) established 
a simaltaneous method for analysis of metformin 
in presence fo H-2 receptor antagonist as well as in 
presence of captopril and lisinopril. Sultana et al. (2011) 
developed HPLC-UV method for analysis of diltiazem 
in association with anti-diabetics drugs, capable in both 
pharmaceuticals and human serum. LC-MS/MS method 
has been comprehended by Ding et al. (2007), Ho et al. 
(2004), Lin et al. (2003), Mistri, Jangid, Shrivastav (2007) 
and Wang, Miksa (2007) to analyze anti-diabetic drugs. 
However, despite of all these reports, literature is short 
on the simultaneous quantification of MF, GP, PGH, 
RG, and SGP. The objective of this endeavor was to 
produce a rapid, reliable and accurate RP-HPLC method 
for the quantification of the aforesaid five antidiabetic 
drugs, simultaneously in pharmaceutical preparations 
and in physiological samples, covering clinical level 
concentration. Substantial method validation study 
was performed and the proposed method holds well for 




MF (99.4%),  GP (98 .3%),  PGH (99 .2%), 
RGM (99.3%) and SG (99.5%) were gifted by local 
pharmaceutical company. Commercial product containing 
these drugs were procured from local market. HPLC 
grade chemicals and solvents were used for mobile phase 
preparation. Phosphoric acid, diethyl amine and triethyl 
amine were from Merck (Germany), methanol, acetonitrile 
were from Fisher scientific (UK). Dosage formulations of 
MF, GP, SGP, PGH and RGM were procured from the local 
market. Blank blood was procured from national institute 
of cardiovascular diseases Karachi. 
HPLC system of Schimadzu Corporation consisting 
of SIL 20A auto injector, LC-20 AT pump, SPD 20A 
prominence UV/VIS detector controlled by LC solution 
software was used in this study. Other equipments include 
Sartorius analytical balance (TE2145), UV-visible 
Shimadzu spectrophotometer (1650 PC) with UV Probe 
software, and pH meter (Jenway 3240). 
Chromatographic resolutions of the peaks were 
achieved with a Nucleosil® C18 HPLC column (4.6 x 
250 mm; 5 µm). Mobile phase consist of acetonitrile: 
FIGURE 1 - Structure of the studied drugs.
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phosphate buffer: methanol (40/40/20) pH 2.0, drawn at 
a flow rate of 1 mL/min, with a detecting wavelength of 
240 nm, at ambient temperature.
Preparation of standard solutions
Standard primary stock solution of 100 µg/mL 
were arranged individually in amber volumetric flask, for 
each analyte in diluent (mobile phase). Stock solutions 
were further diluted and mixed together appropriately to 
obtain a composite solution of required concentrations 
for all the analytes. A volume of 20-μL was injected in to 
the chromatographic system and was analyzed under the 
given conditions.
Preparation of pharmaceutical sample
Stock sample solution of 100 µg/mL of each drug 
were prepared by taking a finally grounded homogenous 
bulk sample of each drug product into an amber glass 
volumetric flask, 30 mL diluent was added, followed by 
sonication and shaking for 15 minutes each. After volume 
correction, further dilutions were made to get the required 
concentration for each drug.
Preparation of in-vitro urine and plasma sample
Urine was collected from healthy volentears. 
Plasma was obtained by mixing blood with heparin 
and centrifugation at 15,000 rpm for few minutes and 
was stocked at -20 ○C for pending analysis. In a 5 mL 
volumetric flask 1 mL of urine or plasma sample was added 
individually, followed by the addition of 1 ml of stock 
composite solution and 2 mL of diluent. After sonication 
and stirring for few minutes the sample was diluted up to 
the mark level. Further dilutions were made according 
to the requirements and before HPLC analysis samples 
were passed through 0.45µm filter (Karlsen, Blomhoff, 
Gundersen, 2005; Wang, Miksa, 2007; Siddiqui et al., 
2013; Siddiqui et al., 2014; Siddiqui et al., 2017).
Method validation
Method validation studies were performed as guided 
by international conference on hormonization. It includes 
linearity and range, specifity, accuracy, precision as well 
as robustness (ICH, 2005). Before method validation, 
justification of system suitability was established by 
injecting five replicates of the same composite standard 
solution. Degree of reproducibility, tailing factor and 
column efficiency were calculated.
Specificity and robustness
Specifity is the determination of an analyte 
unequivocally in presence of coaddetives or other 
ingredients that are supposed to be present in a sample. 
Plasma, urine as well as pharmaceutical excipients 
were fortified with these drugs and invistigated through 
the proposed method. Similary method was tested for 
small but deliberate variation expected during day today 
analysis. Solution stability was also checked by placing 
composite standard solution in refregerator for 48 hours 
(Sher et al., 2014).
Linearity and range
Linearity is the verification through a mathamtical 
procedure that a given method produced results 
proportionate to concentration of the analyte. A range of 
concentraton 25-10000 ng mL-1 of standard composite 
solutions were prepared by diluting stock standard 
composite solution. Linearity was determined by plotting 
peak area vs concentrtion which produced least-square 
regression calibration curves (Sher et al., 2015). 
Quantification and detection limit
Limits of detection (LOD) and quantitation (LOQ) 
were evaluated by applying empirical formula i.e, 
3.3(σ/s) for LOD and 10(σ/s) for LOQ, where σ is the 
standard deviation of the response and S is the slope of 
the calibration curve.
Accuracy and precision 
The closeness of resutls to the individual reading 
when a bulk homogenous sample is subjected to multiple 
analysis is known as precision while, the closeness of 
experimental results to the true value is called as method 
accuracy. Multiple analysis were conducted on urine, 
plasma and pharmaceuticals and percent relative standard 
deviation were determined to present precision. Percent 
recovery was used to describe accuracy of the method. 
Sample were studied in a range of concentration covering 
low, middle and high concentration (Sher et al., 2016).
RESULTS
Acetonitrile: Phsphate buffer: methanol (40/40/20 
v/v) pH 2.0, was found to be suitable mobile phase 
with established flow rate of 1 mL/min and detecting 
wavelength of 240 nm. Typical chromatogram are shown 
in Figures 2-6, which shows retention time for MF at 5.9, 
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SG at 9.1, RGM at 10.9, PGH at 12.6 and GP at 13.8. 
Before application, projected method was validated in line 
with ICH guidelines (ICH, 2005). 
Stock composite standard solution of 100 μg/mL 
was serially diluted to get a range of concentration 
covering low and high dosage.  Before method 
validation system suitability was ensured by calculating 
reproducibility, tailing factor and column efficiency as well 
as peak resolution. Reporduciblity of less than 0.5% was 
witnessed. Tailing factor ranged from 1.03-1.34, column 
efficiency ranged from 9480-26832, while resolution 
ranged from 4.4-9.4 as shown in Table I, which shows 
excellent chromatographic setup at the outset. After 
chromatography the calibration curve was produced by 
constructing plot of peak area vs. concentrations. Linearity 
FIGURE 2 - Chromatogram in API .1=Metformin, 2=Sitagliptin, 
3= Rosiglitazone, 4=Pioglitazone, 5=Glimepiride.
FIGURE 3 - Chromatogram in Urine samples.1=Metformin, 
2=Sitagliptin, 3= Rosiglitazone, 4=Pioglitazone, 5=Glimepiride.
FIGURE 4 - Chromatogram in plasma samples.1=Metformin, 
2=Sitagliptin, 3= Rosiglitazone, 4=Pioglitazone, 5=Glimepiride.
FIGURE 5 - Blank urine.
FIGURE 6 - Blank plasma.
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correlation coefficient value as well as sensitivity test 
such as limit of detection and limit of quantification were 
calculated statistically. Limit of detection was defined 
as LOD = 3.3σ/S, while quantification LOQ = 10σ/S. 
The values were experimentally evaluated through 
chromatography while gradually decreasing analytes 
concentration. A signal-to-noise ratio of 3:1 was 
established for LOD, while 10:1 for LOQ, respectively.
Table II shows study range of 25-10000 ng/mL, 
correlation coefficient of more than 0.9990 as obtained 
with detection limit of 0.52-0.90 ng/mL and quantification 
limit of 1.6-4.5 ng/mL.These results indicates excellent 
linearity of the porposed method in the given range. As 
shown in Table III, plasma samples and urine samples 
recovery ranged from 96-101.8% with %RSD values 
from 1.5-2.4%. Pharmaceutical sample recovery ranged 
from 98-101% with %RSD values from 0.8-1.4%. More 
than 96% accuracy has been established and over all 
precision of less than 2% is shown in pharmaceutical 
while maximum 2.0% precision was exhibited in urine 
and plasma samples.
DISCUSSION
Plasma level RP-HPLC UV quantification of the 
five anti-diabetic drugs i.e., MF, PGH, RGM, GP and SGP, 
was the main objective of this study. These molecules 
are shown in Figure 1. MF and SGP were soluble in 
water, whereas PGH, RG and GP were soluble in organic 
solvent. Early experiments suggested phosphate buffer 
and acetonitrile combination a better option of mobile 
phase. However, this combination (60:40 v/v) resulted 
in late elution of SGP. Moreover, peak of RGM and 
PGH merged together. Acetonitrile addition negatively 
impacted the separation. However, by increasing aqueous 
part of mobile phase (40:60 v/v), PPARs were separated 
but it resulted in late elution of SGP with distracted peak 
symmetry, owing to strong interaction with stationary 
phase at high pH. Decreasing pH gradually resolved the 
two PPARs, however, owing to probably basic nature of 
SGP, its peak was broad due to strong interaction with 
stationary phase. Methanol was added to mobile phase to 
increase polarity and at last, acetonitrile: phosphate buffer: 
methanol (40/40/20 v/v) pH 2.0 was found to be a suitable 
mobile phase. Decreasing pH below 2.0 resulted in very 
early elution showing little retention, especially in case 
of MF and SGP owing to their hydrophilic basic nature. 
Earlier simple mobile phases such as aqueous 
methanol and aqueous acetonitrile were tried, but 
unsatisfactory and poorly resolved peaks were obtained. 
Best separation was achieved with Nucleosil C18 analytical 
column, although, other analytical columns such as C18 
and C8 of different brands were also evaluated. Excellent 
chromatographic resolution as shown in Table I and 
Figure 2-6 is granted with sound sensitivity, when mobile 
phase was drawn at flow rate of 1 mL/min and detected 
with 240 nm wavelength. This resulted in a fast, accurate 
and reliable analysis of the five anti-diabetic drugs in 
simultaneous mood in pharmaceuticals and physiological 
fluids. The method was found to be free of interference 
from endogenous plasma and other excipients and 
sensitive enough to determine these drugs in concentration 
as low as 25 ng/mL as shown in Table II and III. Substantial 
method validation studies were conducted to establish 
validity of the method. Figure 2-6, shows selective and 
TABLE 1 - System suitability
Sr. No. Parameter Result found (range)
1 %RSD of five replicates (NMT2%) 0.05- 0.52
2 Tailing factor (T) (NMT 2) 1.03-1.34
3 Theoretical plates (N) (NLT:4000) 9480-26832
4 Resolution (R) 4.4-9.4
TABLE II - Linearity and sensitivity of the method
Parameter
Inference
MF GP PGH RGM SG
Linearity range (ng /mL) 25-10000 25-10000 25-10000 25-10000 25-10000
Correlation coefficient 0.9998 0.9992 0.9995 0.9997 0.9993
Slope 81005.1 32025.5 66684.1 64327.6 28430.2
Intercept -2531 -1113 -2098 -2101 -1007
(LOD) (ng /mL) 0.52 0.88 0.66 0.73 0.90
(LOQ) (ng /mL) 1.62 3.96 2.56 2.33 4.55
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specific determination of the ingredients, while, Table II 
and III shows excellent linearity, accuracy and precision 
in a wide range.
CONCLUSION
The method facilitates simultaneous determination 
of MF, GP, SGP, PGH and RGM. The newly developed 
LC-method is cost-effective, rapid, and sensitive enough 
to assess plasma level qunatification of analytes under the 
study. Short chromatographic run time, less sample volume 
and low limit of quantification are highly appreciated from 
routine quality control perspective. The developed method 
is more than simple and robust, and statistical results 
suggest validity of the method. Reliability, sensitivity, 
rapidness, good recovery and precision as well as wide 
applications of the projected method present superiority 
over the other reported HPLC methods.
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